Search

Your search keyword '"Manouchehr Khazandi"' showing total 5 results
Start Over Author "Manouchehr Khazandi" Publisher public library of science (plos)
5 results on '"Manouchehr Khazandi"'

1. Decontamination of aerosolised bacteria from a pig farm environment using a pH neutral electrochemically activated solution (Ecas4 anolyte).

Author

Sangay Tenzin, Abiodun David Ogunniyi, Manouchehr Khazandi, Sergio Ferro, Jonathon Bartsch, Simon Crabb, Sam Abraham, Permal Deo, and Darren J Trott

Subjects
Medicine, Science
Abstract

An electrochemically activated solution (ECAS), generated by electrolysis of a dilute sodium chloride solution in a four-chamber electrolytic cell (Ecas4), was tested as a sanitising aerosol in eliminating bacteria from the environment of a weaning room vacated 24-48h earlier, at a continuous flow pig farm. An ultrasonic humidifier was used to fill the environment with a fog (droplets with diameters of 1-5 μm) containing 0.25 ppm of hypochlorous acid. The weaning room was fogged for 3 min at 30 min intervals during five hours of aerosol disinfection. An innovative sample treatment with propidium monoazide dye in conjunction with cyclonic air sampling was optimised and adapted for discerning live/dead bacteria in subsequent molecular quantification steps. Without fogging, total bacterial load ranged from 5.06 ± 0.04 to 5.75 ± 0.04 Log10 CFU/m3. After the first hour of fogging, a 78% total bacterial reduction was observed, which further increased to > 97% after the second hour, > 99.4% after the third and 99.8% after the fourth hour, finally resulting in a 99.99% reduction from the farm environment over five hours. Unlike the current formaldehyde spray disinfection protocol, which requires a long empty period because of its hazardous properties, this economically viable and environmentally friendly disinfection protocol may significantly lower downtime. Moreover, ECAS fogging can be easily adapted to a variety of applications, including the elimination of pathogens from livestock farm air environment for disease prevention, as well as decontamination after disease outbreaks.

Published
2019
Full Text
View/download PDF

2. Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing.

Author

Abiodun D Ogunniyi, Zlatko Kopecki, Elizabeth E Hickey, Manouchehr Khazandi, Emma Peel, Katherine Belov, Alexandra Boileau, Sanjay Garg, Henrietta Venter, Wei Yee Chan, Peter B Hill, Stephen W Page, Allison J Cowin, and Darren J Trott

Subjects
Medicine, Science
Abstract

There are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness scald wound infection and sepsis that mimic disease pathogenesis in humans and animals using a recombinant luciferase-expressing Staphylococcus aureus strain (Xen29). Two days post-scald wound infection, mice were treated twice daily with a 2% topical mupirocin ointment for 7 days. For sepsis experiments, mice were treated intraperitoneally with 6 mg/kg daptomycin 2 h and 6 h post-infection and time to moribund monitored for 72 h. Consistent bacterial burden data were obtained from individual mice by regular photon intensity quantification on a Xenogen IVIS Lumina XRMS Series III biophotonic imaging system, with concomitant significant reduction in photon intensities in drug-treated mice. Post-mortem histopathological examination of wounds and bacterial counts in blood correlated closely with disease severity and total flux obtained from Xen29. The bioluminescent murine models provide a refinement to existing techniques of multiple bacterial enumeration during disease pathogenesis and promote animal usage reduction. The models also provide an efficient and information-rich platform for preclinical efficacy evaluation of new drug classes for treating acute and chronic human and animal bacterial infections.

Published
2018
Full Text
View/download PDF

3. Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.

Author

Abiodun D Ogunniyi, Manouchehr Khazandi, Andrew J Stevens, Sarah K Sims, Stephen W Page, Sanjay Garg, Henrietta Venter, Andrew Powell, Karen White, Kiro R Petrovski, Geraldine Laven-Law, Eliane G Tótoli, Hérida R Salgado, Hongfei Pi, Geoffrey W Coombs, Dean L Shinabarger, John D Turnidge, James C Paton, Adam McCluskey, and Darren J Trott

Subjects
Medicine, Science
Abstract

The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetraacetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens.

Published
2017
Full Text
View/download PDF

4. Bioluminescent murine models of bacterial sepsis and scald wound infections for antimicrobial efficacy testing

Author

Katherine Belov, Abiodun D. Ogunniyi, Manouchehr Khazandi, Peter B. Hill, Sanjay Garg, Zlatko Kopecki, Stephen W. Page, Alexandra R Boileau, Darren J. Trott, Henrietta Venter, Emma Peel, Allison J. Cowin, Wei Yee Chan, Elizabeth E. Hickey, Ogunniyi, Abiodun D, Kopecki, Zlatko, Hickey, Elizabeth E, Khazandi, Manouchehr, Peel, Emma, Belov, Katherine, Boileau, Alexandra, Garg, Sanjay, Venter, Henrietta, Chan, Wei Yee, Hill, Peter B, Page, Stephen W, Cowin, Allison J, and Trott, Darren J

Subjects
0301 basic medicine, Male, Bacterial Diseases, Physiology, Staphylococcus, lcsh:Medicine, Bacteremia, Disease, medicine.disease_cause, Pathology and Laboratory Medicine, sepsis, chemistry.chemical_compound, Mice, Medicine and Health Sciences, lcsh:Science, Multidisciplinary, Physics, Animal Models, Staphylococcal Infections, 3. Good health, Anti-Bacterial Agents, Bacterial Pathogens, Mupirocin, Infectious Diseases, Experimental Organism Systems, Staphylococcus aureus, Medical Microbiology, Physical Sciences, Pathogens, Burns, Elementary Particles, medicine.drug, Research Article, 030106 microbiology, Mouse Models, Microbial Sensitivity Tests, Staphylococcal infections, Research and Analysis Methods, Microbiology, antimicrobials, Sepsis, 03 medical and health sciences, Model Organisms, Signs and Symptoms, Diagnostic Medicine, Tissue Repair, medicine, Animals, Animal Models of Disease, Particle Physics, Microbial Pathogens, Photons, Bacteria, business.industry, lcsh:R, Organisms, Biology and Life Sciences, medicine.disease, Disease Models, Animal, Luminescent Proteins, Animal Models of Infection, wound infections, chemistry, bacterial infections, Concomitant, Wound Infection, Animal Studies, lcsh:Q, Daptomycin, business, Physiological Processes
Abstract

There are very few articles in the literature describing continuous models of bacterial infections that mimic disease pathogenesis in humans and animals without using separate cohorts of animals at each stage of disease. In this work, we developed bioluminescent mouse models of partial-thickness scald wound infection and sepsis that mimic disease pathogenesis in humans and animals using a recombinant luciferase-expressing Staphylococcus aureus strain (Xen29). Two days post-scald wound infection, mice were treated twice daily with a 2% topical mupirocin ointment for 7 days. For sepsis experiments, mice were treated intraperitoneally with 6 mg/kg daptomycin 2 h and 6 h post-infection and time to moribund monitored for 72 h. Consistent bacterial burden data were obtained from individual mice by regular photon intensity quantification on a Xenogen IVIS Lumina XRMS Series III biophotonic imaging system, with concomitant significant reduction in photon intensities in drug-treated mice. Post-mortem histopathological examination of wounds and bacterial counts in blood correlated closely with disease severity and total flux obtained from Xen29. The bioluminescent murine models provide a refinement to existing techniques of multiple bacterial enumeration during disease pathogenesis and promote animal usage reduction. The models also provide an efficient and information-rich platform for preclinical efficacy evaluation of new drug classes for treating acute and chronic human and animal bacterial infections. Refereed/Peer-reviewed

Published
2018

5. Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent

Author

Hérida Regina Nunes Salgado, Sanjay Garg, Andrew Stevens, Geoffrey W. Coombs, Hongfei Pi, Abiodun D. Ogunniyi, Eliane Gandolpho Tótoli, Dean L. Shinabarger, Geraldine Laven-Law, Manouchehr Khazandi, Kiro R. Petrovski, James C. Paton, Karen L. White, Sarah K. Sims, Darren J. Trott, Adam McCluskey, Andrew K. Powell, Henrietta Venter, John D. Turnidge, Stephen W. Page, Ogunniyi, Abiodun D, Khazandi, Manouchehr, Stevens, Andrew J, Sims, Sarah K, Page, Stephen W, Garg, Sanjay, Venter, Henrietta, Powell, Andrew, White, Karen, Petrovski, Kiro R, Laven-Law, Geraldine, Tótoli, Eliane G, Salgado, Hérida R, Pi, Hongfei, Coombs, Geoffrey W, Shinabarger, Dean L, Turnidge, John D, Paton, James C, McCluskey, Adam, Trott, Darren J, Univ Adelaide, Univ Newcastle, Neoculi Pty Ltd, Univ South Australia, Monash Univ, Universidade Estadual Paulista (Unesp), Fiona Stanley Hosp, Murdoch Univ, and Micromyx LLC

Subjects
0301 basic medicine, Time Factors, Physiology, Polymyxin, Staphylococcus, Cell Membranes, lcsh:Medicine, medicine.disease_cause, Pathology and Laboratory Medicine, chemistry.chemical_compound, Mice, Medicine and Health Sciences, lcsh:Science, Antibacterial agent, Multidisciplinary, Antimicrobials, Drugs, Pneumococcus, Antimicrobial, 3. Good health, Anti-Bacterial Agents, Bacterial Pathogens, Body Fluids, Electrophysiology, Streptococcus pneumoniae, Blood, Medical Microbiology, Microsomes, Liver, Pathogens, Cellular Structures and Organelles, Anatomy, Research Article, Staphylococcus aureus, Gram-negative bacteria, Robenidine, medicine.drug_class, 030106 microbiology, Microbial Sensitivity Tests, Biology, Hemolysis, Microbiology, Membrane Potential, Blood Plasma, Cell Line, 03 medical and health sciences, Structure-Activity Relationship, Antibiotic resistance, Vancomycin, Microbial Control, Drug Resistance, Bacterial, medicine, Animals, Humans, Microbial Pathogens, Pharmacology, Bacteria, Pseudomonas aeruginosa, Cell Membrane, lcsh:R, Organisms, Biology and Life Sciences, Streptococcus, Cell Biology, biology.organism_classification, Multiple drug resistance, chemistry, lcsh:Q, Antimicrobial Resistance, Enterococcus
Abstract

Made available in DSpace on 2018-11-26T17:40:30Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-09-05 Australian Research Council (ARC) Neoculi Pty Ltd National Health and Medical Research Council of Australia (NHMRC) University of South Australia Sansom Institute of Health Research Micromyx LLC The spread of multidrug resistance among bacterial pathogens poses a serious threat to public health worldwide. Recent approaches towards combating antimicrobial resistance include repurposing old compounds with known safety and development pathways as new antibacterial classes with novel mechanisms of action. Here we show that an analog of the anticoccidial drug robenidine (4,6-bis(2-((E)-4-methylbenzylidene)hydrazinyl)pyrimidin-2-amine; NCL195) displays potent bactericidal activity against Streptococcus pneumoniae and Staphylococcus aureus by disrupting the cell membrane potential. NCL195 was less cytotoxic to mammalian cell lines than the parent compound, showed low metabolic degradation rates by human and mouse liver microsomes, and exhibited high plasma concentration and low plasma clearance rates in mice. NCL195 was bactericidal against Acinetobacter spp and Neisseria meningitidis and also demonstrated potent activity against A. baumannii, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Enterobacter spp. in the presence of sub-inhibitory concentrations of ethylenediaminetetraacetic acid (EDTA) and polymyxin B. These findings demonstrate that NCL195 represents a new chemical lead for further medicinal chemistry and pharmaceutical development to enhance potency, solubility and selectivity against serious bacterial pathogens. Univ Adelaide, Sch Anim & Vet Sci, Australian Ctr Antimicrobial Resistance Ecol, Roseworthy, SA, Australia Univ Newcastle, Sch Environm & Life Sci, Chem, Callaghan, NSW, Australia Univ Adelaide, Sch Anim & Vet Sci, Roseworthy, SA, Australia Neoculi Pty Ltd, Burwood, Vic, Australia Univ South Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Ctr Pharmaceut Innovat & Dev, Adelaide, SA, Australia Univ South Australia, Sansom Inst Hlth Res, Sch Pharm & Med Sci, Adelaide, SA, Australia Monash Univ, Monash Inst Pharmaceut Sci, Ctr Drug Candidate Optimisat, Parkville, Vic, Australia Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Drugs & Med, Sao Paulo, Brazil Fiona Stanley Hosp, Path West Lab Med WA, Dept Microbiol, Murdoch, WA, Australia Murdoch Univ, Sch Vet & Life Sci, Murdoch, WA, Australia Micromyx LLC, Kalamazoo, MI USA Univ Adelaide, Sch Biol Sci, Dept Mol & Cellular Biol, Adelaide, SA, Australia Univ Adelaide, Sch Biol Sci, Dept Mol & Cellular Biol, Res Ctr Infect Dis, Adelaide, SA, Australia Sao Paulo State Univ, Sch Pharmaceut Sci, Dept Drugs & Med, Sao Paulo, Brazil Australian Research Council (ARC): LP110200770 National Health and Medical Research Council of Australia (NHMRC): 565526 National Health and Medical Research Council of Australia (NHMRC): 627142

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results